WebJun 20, 2024 · BlackThorn Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the lives of people with neurobehavioral disorders through the discovery and development of novel ... WebBTRX-335140. BTRX-335140, also known by its other developmental code names BTRX-140, CYM-53093, and NMRA-140, is an opioid antagonist medication which is under development for the treatment of depression. [1] [2] [3] It is specifically a selective κ-opioid receptor antagonist and is under development for major depressive disorder.

Stock Market

Web BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system (CNS) disorders. WebDec 14, 2024 · Over the past 3 years, D.A.P. received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Otsuka and … buff\\u0027s a3

BLACKTHORN - Uses, Side Effects, and More - WebMD

WebJun 12, 2024 · Ways to buy and sell Blackthorn Therapeutics shares pre-IPO. Invest in proven Healthcare private companies like Blackthorn Therapeutics at ForgeGlobal.com. … WebNov 5, 2024 · BlackThorn Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the lives of people with neurobehavioral disorders. BlackThorn has created a robust pipeline of ... WebOct 7, 2024 · Neumora's NMRA-140, a kappa opioid receptor antagonist previously developed by Blackthorn Therapeutics In one of the largest biotech debuts this year, … buff\u0027s a1